Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 1-4/2008

01-03-2008

Choice of Radiotherapy Planning Modality Influences Toxicity in the Treatment of Locally Advanced Esophageal Cancer

Authors: Heath B. Mackley, Jonathan S. Adelstein, Chandana A. Reddy, David J. Adelstein, Thomas W. Rice, Jerrold P. Saxton, Gregory M. M. Videtic

Published in: Journal of Gastrointestinal Cancer | Issue 1-4/2008

Login to get access

Abstract

Purpose

Three-dimensional computed tomography-based radiotherapy planning (3DCTP) is increasingly employed in the treatment of esophageal cancer. It is unknown whether a 3DCTP approach influences outcomes compared to two-dimensional planning (2DP). This study compares clinical outcomes for homogenously treated patient cohorts stratified by planning modality.

Methods and Materials

A retrospective chart review was conducted on patients with T3/4 and/or node-positive esophageal carcinoma treated at the Cleveland Clinic between July 1, 2003 and May 31, 2006 who were managed with an institutional regimen consisting of preoperative radiotherapy, whether 3DCTP or 2DP [30 Gy/20 fractions/1.5 Gy twice daily over 2 weeks], with concurrent cisplatin and 5-fluorouracil the first week. Following definitive resection, an identical postoperative course of concurrent chemoradiotherapy (CRT) was delivered.

Results

One hundred and forty-one patients completed preoperative CRT and were available for review. The median follow-up of living patients is 21.7 months. Fifty-five percent underwent 3DCTP and 45% had 2DP. The treatment groups were similar, with the exception of clinical stage group, with 2DP having more stage II and fewer stage III patients than 3DCTP (p = 0.02). 3DCTP plans had significantly smaller field sizes by area (p < 0.0001). Pathologic response, locoregional control, distant control, and overall survival were equivalent between the two planning modalities. Esophagitis was significantly less common with a 3D approach compared to 2D planning (49% vs. 71%, p = 0.0096), with other toxicities equivalent between the groups.

Conclusions

3DCTP reduces acute esophagitis in patients receiving multimodality therapy for esophageal cancer without compromising clinical outcomes.
Literature
1.
go back to reference American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006. American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006.
4.
go back to reference MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30. doi:10.1056/NEJMoa010187.PubMedCrossRef MacDonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30. doi:10.​1056/​NEJMoa010187.PubMedCrossRef
5.
go back to reference Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.PubMed Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326:1593–8.PubMed
6.
go back to reference Smith TJ, Ryan LM, Douglass HO, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:269–76. doi:10.1016/S0360-3016(98)00232-6.PubMed Smith TJ, Ryan LM, Douglass HO, et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys. 1998;42:269–76. doi:10.​1016/​S0360-3016(98)00232-6.PubMed
9.
go back to reference Nishioka T, Shirato H, Arimoto T, et al. Reduction of radiation-induced xerostomia in nasopharyngeal carcinoma using CT simulation with laser patient marking and three-field irradiation technique. Int J Radiat Oncol Biol Phys. 1997;38:705–12. doi:10.1016/S0360-3016(97)00054-0.PubMedCrossRef Nishioka T, Shirato H, Arimoto T, et al. Reduction of radiation-induced xerostomia in nasopharyngeal carcinoma using CT simulation with laser patient marking and three-field irradiation technique. Int J Radiat Oncol Biol Phys. 1997;38:705–12. doi:10.​1016/​S0360-3016(97)00054-0.PubMedCrossRef
10.
go back to reference Jabbari S, Kim HM, Eisbruch A, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys. 2005;63:725–31. doi:10.1016/j.ijrobp.2005.02.045.PubMed Jabbari S, Kim HM, Eisbruch A, et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report. Int J Radiat Oncol Biol Phys. 2005;63:725–31. doi:10.​1016/​j.​ijrobp.​2005.​02.​045.PubMed
11.
go back to reference Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1309–17. doi:10.1016/j.ijrobp.2006.11.012.PubMed Graff P, Lapeyre M, Desandes E, et al. Impact of intensity-modulated radiotherapy on health-related quality of life for head and neck cancer patients: matched-pair comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1309–17. doi:10.​1016/​j.​ijrobp.​2006.​11.​012.PubMed
12.
go back to reference Vuong T, Kopek N, Ducruet T, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1394–400. doi:10.1016/j.ijrobp.2006.11.038.PubMed Vuong T, Kopek N, Ducruet T, et al. Conformal therapy improves the therapeutic index of patients with anal canal cancer treated with combined chemotherapy and external beam radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1394–400. doi:10.​1016/​j.​ijrobp.​2006.​11.​038.PubMed
13.
go back to reference Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438–44. doi:10.1016/j.ijrobp.2006.11.005.PubMed Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438–44. doi:10.​1016/​j.​ijrobp.​2006.​11.​005.PubMed
17.
go back to reference Guzel ZB, Childs JL, Nahum PJ, et al. A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. Br J Radiol. 1998;71:1076–82.PubMed Guzel ZB, Childs JL, Nahum PJ, et al. A comparison of conventional and conformal radiotherapy of the oesophagus: work in progress. Br J Radiol. 1998;71:1076–82.PubMed
19.
go back to reference Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIa/IIIb non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–56. doi:10.1016/S0360-3016(02)02958-9.PubMed Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIa/IIIb non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys. 2002;54:348–56. doi:10.​1016/​S0360-3016(02)02958-9.PubMed
22.
go back to reference Fang LC, Komaki R, Allen P, et al. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:108–16. doi:10.1016/j.ijrobp.2006.04.015.PubMed Fang LC, Komaki R, Allen P, et al. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:108–16. doi:10.​1016/​j.​ijrobp.​2006.​04.​015.PubMed
24.
go back to reference Antonadou D, Coliarakis N, Syndoinou M, et al. Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–22. doi:10.1016/S0360-3016(01)01713-8.PubMed Antonadou D, Coliarakis N, Syndoinou M, et al. Randomized phase III trial of radiation treatment +/− amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2001;51:915–22. doi:10.​1016/​S0360-3016(01)01713-8.PubMed
25.
go back to reference Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57:402–8. doi:10.1016/S0360-3016(03)00590-X.PubMedCrossRef Antonadou D, Throuvalas N, Petridis A, et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003;57:402–8. doi:10.​1016/​S0360-3016(03)00590-X.PubMedCrossRef
26.
go back to reference Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002;12:46–9. doi:10.1053/srao.2002.31363.PubMedCrossRef Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002;12:46–9. doi:10.​1053/​srao.​2002.​31363.PubMedCrossRef
Metadata
Title
Choice of Radiotherapy Planning Modality Influences Toxicity in the Treatment of Locally Advanced Esophageal Cancer
Authors
Heath B. Mackley
Jonathan S. Adelstein
Chandana A. Reddy
David J. Adelstein
Thomas W. Rice
Jerrold P. Saxton
Gregory M. M. Videtic
Publication date
01-03-2008
Publisher
Humana Press Inc
Published in
Journal of Gastrointestinal Cancer / Issue 1-4/2008
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-009-9067-x

Other articles of this Issue 1-4/2008

Journal of Gastrointestinal Cancer 1-4/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.